Quarterly Report/Invoice Clause Samples
Quarterly Report/Invoice. Within thirty (30) days following the end of each calendar quarter, ACTII shall provide Amylin with a report detailing third person costs incurred as described in Section 4.7(a), together with the actual time spent by ACTII personnel (including a breakdown of the names of the employees working on the development program and the number of hours billed under the Product Development Plan by each employee during such calendar quarter). Amylin, or its representatives, shall have the right to audit (with financial and scientific representatives) ACTII records with respect to such reports, in accordance with Section 4.7(d).
Quarterly Report/Invoice. Within [ * ] following the end of each Calendar Quarter, ICOS and Lilly each shall prepare a report (the "Invoice") detailing the Non-Sales Force Promotion Expenses and Sales Force Promotion Expenses incurred in the prior Calendar Quarter. Within [ * ] following the end of each Calendar Quarter, ICOS and ▇▇▇▇▇ will each forward its Invoice to the Company with a copy to the other party for review and approval by a designated representative of each party. Sufficient detail shall be provided to support the expenses being charged. If an objection by a party with respect to an Invoice is not raised within [ * ] of receipt thereof, such Invoice will be deemed approved (such approval shall not be construed as a waiver of any audit or * Confidential Treatment Requested other rights related thereto). Once approved as described above in this Section 7.3, each invoice will be submitted to the Company for payment in accordance with the terms set forth in Section 7.4, below, of this Agreement. If necessary, adjustments or corrections to an Invoice as agreed to by both ICOS and ▇▇▇▇▇ will be made to the Invoice before it is submitted for payment. Otherwise adjustments will be made in the subsequent Invoice. The Company, or its representatives, shall have the right to audit both ICOS and Lilly records with respect to such reports, in accordance with Section 8.2(D), below, of this Agreement.
Quarterly Report/Invoice. Unless the Parties agree to a different procedure, within forty-five (45) days following the end of each Calendar Quarter, ICOS and Lilly each will prepare a report (the “Invoice”) Detailing (a) Marketing and Other Selling Expenses, Allocated Business-to-Business Expenses, FDA Risk Management Expenses and IMS Data Expenses incurred and (b) Sales Force Promotional Effort Expenses incurred in each country within the Shared Territory during the prior Calendar Quarter. Within forty-five (45) days following the end of each Calendar Quarter, ICOS and Lilly will each forward its Invoice to the Company with a copy to the other Party for review and approval by a designated representative of each Party. Each Party shall provide sufficient Detail with each Invoice to support the expenses being charged and will make available to the other Parties all underlying supporting documentation and records. If an objection by a Party with respect to an Invoice is not raised within fifteen (15) days of receipt thereof, such Invoice will be deemed approved (such approval will not be construed as a waiver of any audit or other rights related thereto). Once approved as described above, each invoice will be submitted to the Company for payment in accordance with the terms set forth in Section 7.8. If necessary, adjustments or corrections to an Invoice as agreed to by ICOS and Lilly will be made before the Invoice is submitted to the Company for payment. The Company, or its representatives, will have the right to audit both ICOS and Lilly records with respect to such Invoices, in accordance with Section 8.2(D).